Pharmaceutical applications of the Calu-3 lung epithelia cell line

被引:71
作者
Ong, Hui Xin [1 ,2 ]
Traini, Daniela [1 ,2 ]
Young, Paul M. [1 ,2 ]
机构
[1] Woolcock Inst Med Res, Glebe, NSW 2037, Australia
[2] Univ Sydney, Sydney Med Sch, Discipline Pharmacol, Glebe, NSW 2006, Australia
关键词
Calu-3; drug deposition; drug transport; metabolism; pulmonary delivery; P-GLYCOPROTEIN ACTIVITY; PULMONARY DRUG-DELIVERY; HUMAN TUMOR XENOGRAFTS; GROWTH-FACTOR RECEPTOR; IN-VITRO; TRANSFECTION EFFICIENCY; CHITOSAN NANOPARTICLES; RESPIRATORY EPITHELIA; TRACHEAL EPITHELIUM; ANTITUMOR-ACTIVITY;
D O I
10.1517/17425247.2013.805743
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Introduction: The Calu-3 lung cell line has been shown to be a promising in vitro model of airway epithelia due to its similarity to in vivo physiology. Hence, over the past decade, it has found increasing applications in the pharmaceutical industry. Areas covered: This review focuses on the pharmaceutical applications of the Calu-3 cell line in areas such as mechanisms of drug transport, studying aerosol deposition, controlled release studies and identification of possible drug-drug interactions. The main findings of various studies, as well as the predictive potential of this model, are presented and discussed in this review. Expert opinion: There is still a lack of mechanistic knowledge regarding transport of inhaled therapeutics across the lungs. Cell culture models such as Calu-3 provide a simple and reproducible system to study the underlying mechanisms by which inhaled therapeutics interact with the lungs. However, more complex systems that integrate particle deposition onto different cell culture systems may be useful in addressing some fundamental questions to generate a better understanding of determinants that influences pulmonary drug dissolution, absorption, metabolism and efficacy. Ultimately the use of the Calu-3 cell line provides a basic research tool that enables the development of safer and more effective inhaled therapeutics.
引用
收藏
页码:1287 / 1302
页数:16
相关论文
共 94 条
[61]   Rifampicin reduces plasma concentrations of moxifloxacin in patients with tuberculosis [J].
Nijland, H. M. J. ;
Ruslami, R. ;
Suroto, A. Juwono ;
Burger, D. M. ;
Alisjahbana, B. ;
van Crevel, R. ;
Aarnoutse, R. E. .
CLINICAL INFECTIOUS DISEASES, 2007, 45 (08) :1001-1007
[62]   Liposomal Nanoparticles Control the Uptake of Ciprofloxacin Across Respiratory Epithelia [J].
Ong, Hui Xin ;
Traini, Daniela ;
Cipolla, David ;
Gonda, Igor ;
Bebawy, Mary ;
Agus, Helen ;
Young, Paul M. .
PHARMACEUTICAL RESEARCH, 2012, 29 (12) :3335-3346
[63]   Epithelial Profiling of Antibiotic Controlled Release Respiratory Formulations [J].
Ong, Hui Xin ;
Traini, Daniela ;
Bebawy, Mary ;
Young, Paul Michael .
PHARMACEUTICAL RESEARCH, 2011, 28 (09) :2327-2338
[64]   Transport of HIV-protease inhibitors across 1α,25di-hydroxy vitamin D3-treated Calu-3 cell monolayers:: Modulation of P-glycoprotein activity [J].
Patel, J ;
Pal, D ;
Vangala, V ;
Gandhi, M ;
Mitra, AK .
PHARMACEUTICAL RESEARCH, 2002, 19 (11) :1696-1703
[65]   The Particle has Landed-Characterizing the Fate of Inhaled Pharmaceuticals [J].
Patton, John S. ;
Brain, Joseph D. ;
Davies, Lee A. ;
Fiegel, Jennifer ;
Gumbleton, Mark ;
Kim, Kwang-Jin ;
Sakagami, Masahiro ;
Vanbever, Rita ;
Ehrhardt, Carsten .
JOURNAL OF AEROSOL MEDICINE AND PULMONARY DRUG DELIVERY, 2010, 23 :S71-S87
[66]   Identification and functional characterization of breast cancer resistance protein in human bronchial epithelial cells (Calu-3) [J].
Paturi, Durga Kalyani ;
Kwatra, Deep ;
Ananthula, Hari Krishna ;
Pal, Dhananjay ;
Mitra, Ashim K. .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2010, 384 (1-2) :32-38
[67]   Insulin aggregation and asymmetric transport across human bronchial epithelial cell monolayers (Calu-3) [J].
Pezron, I ;
Mitra, R ;
Pal, D ;
Mitra, AK .
JOURNAL OF PHARMACEUTICAL SCIENCES, 2002, 91 (04) :1135-1146
[68]   A novel charges trinuclear platinum complex effective against cisplatin-resistant tumours: hypersensitivity of p53-mutant human tumour xenografts [J].
Pratesi, G ;
Perego, P ;
Polizzi, D ;
Righetti, SC ;
Supino, R ;
Caserini, C ;
Manzotti, C ;
Giuliani, FC ;
Pezzoni, G ;
Tognella, S ;
Spinelli, S ;
Farrell, N ;
Zunino, F .
BRITISH JOURNAL OF CANCER, 1999, 80 (12) :1912-1919
[69]   Delivery of therapeutic levels of heparin and low-molecular-weight heparin through a pulmonary route [J].
Qi, YW ;
Zhao, GL ;
Liu, DF ;
Shriver, Z ;
Sundaram, M ;
Sengupta, S ;
Venkataraman, G ;
Langer, R ;
Sasisekharan, R .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2004, 101 (26) :9867-9872
[70]  
Raben D, 2005, CLIN CANCER RES, V11, P795